stockrowAmgen Inc.
AMGNHealthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −0.16%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. (AMGN) Gross margin
Amgen Inc.'s gross margin over the twelve months to 30 September 2026 was 70.9%, up 3.6 percentage points from fiscal 2025 (67.3%). Over the past ten years it has ranged from 61.5% (fiscal 2024) to 82.7% (fiscal 2018); the current reading is higher than 18% of that period. That is in line with the Drug Manufacturers General industry median of 73.0% and above the Healthcare sector median of 54.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 67.3% | 5.72 |
| FY2024 | 61.5% | (8.49) |
| FY2023 | 70.0% | (5.64) |
| FY2022 | 75.7% | 0.50 |
| FY2021 | 75.2% | (0.61) |
| FY2020 | 75.8% | (5.58) |
| FY2019 | 81.4% | (1.38) |
| FY2018 | 82.7% | 0.54 |
| FY2017 | 82.2% | 0.29 |
| FY2016 | 81.9% | 1.41 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 73.1% | 1.06 |
| Jun 2026 | 72.0% | 3.88 |
| Mar 2026 | 68.2% | (1.68) |
| Dec 2025 | 69.8% | 2.09 |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S compare | 80.9% |
| GILD Gilead Sciences, Inc. compare | 79.9% |
| NVS Novartis AG compare | 74.9% |
| ABBV AbbVie Inc. compare | 73.7% |
| PFE Pfizer Inc. compare | 73.4% |
| MRK Merck & Co., Inc. compare | 71.8% |
| AMGN Amgen Inc. | 70.9% |
| BMY Bristol Myers Squibb Company compare | 69.2% |
| Drug Manufacturers General industry median | 73.0% |
| Healthcare sector median | 54.5% |
| Market median | 46.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement